Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies

This study examined the microtubule inhibitor eribulin in recurrent/metastatic salivary gland cancers (RMSGCs), a disease where no therapeutic standard exists.

[1]  S. Karam,et al.  Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Dziadziuszko,et al.  Abstract 3190: Genomic profiling of salivary gland tumors identifies novel and targetable alterations , 2016 .

[3]  P. Stephens,et al.  Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations , 2016, Clinical Cancer Research.

[4]  J. Gilbert,et al.  Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. , 2016 .

[5]  N. Schultz,et al.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer , 2016, Clinical Cancer Research.

[6]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[7]  D. Hayes,et al.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Odenthal,et al.  Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity , 2015, Oncotarget.

[9]  P. Stephens,et al.  Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies , 2014, The American journal of surgical pathology.

[10]  S. Koyfman,et al.  Biology and management of salivary gland cancers. , 2012, Seminars in radiation oncology.

[11]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[12]  D. Tu,et al.  A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer , 2010, Cancer.

[13]  L. Mariani,et al.  Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. , 2009, Oral oncology.

[14]  D. Hayes,et al.  Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Gilbert,et al.  Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group , 2006, Head & neck.

[16]  E. Lamont,et al.  Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Roodenburg,et al.  Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group , 2004, Head & neck.

[18]  A. Colevas,et al.  Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. , 2003, Oral oncology.

[19]  M. Airoldi,et al.  Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies , 2001, Cancer.

[20]  R. Demicheli,et al.  Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  S. Rodenhuis,et al.  Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Verweij,et al.  Cisplatin‐based chemotherapy in advanced adenoid cystic carcinoma of the head and neck , 1992, Head & neck.

[23]  L. Licitra,et al.  Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients , 1991, Cancer.

[24]  G. Budd,et al.  Adenoid cystic carcinoma of the salivary gland: Sustained complete response to chemotherapy , 1983, Cancer.

[25]  J. Hurley,et al.  Complete response of a metastatic adenoid cystic carcinoma of the parotid gland to chemotherapy , 1981, Cancer.

[26]  A. Garden,et al.  Postoperative radiotherapy for malignant tumors of the parotid gland. , 1997, International journal of radiation oncology, biology, physics.